<DOC>
	<DOC>NCT00485589</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who are naive to methotrexate. Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or ocrelizumab 500mg i.v. on Days 1 and 15. Repeat courses of i.v. treatment will be administered at weeks 24, 52 and 76. All patients will receive concomitant methotrexate (7.5 mg escalating to 20mg p.o. weekly). The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criteria: Age â‰¥ 18 Rheumatoid arthritis for 3 months5 years Naive to methotrexate If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to baseline Exclusion criteria: Rheumatic autoimmune disease or inflammatory joint disease other than RA Prior receipt of any biologic therapy for RA Concurrent treatment with any DMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>FILM</keyword>
	<keyword>RA</keyword>
	<keyword>anti-CD20</keyword>
	<keyword>CD20</keyword>
</DOC>